{"id":62648,"date":"2025-10-07T13:01:19","date_gmt":"2025-10-07T13:01:19","guid":{"rendered":"https:\/\/technopolis-group.com\/report\/evaluation-of-the-uk-vaccine-network-project-1-0-nihr207661-case-studies\/"},"modified":"2025-11-25T08:25:10","modified_gmt":"2025-11-25T08:25:10","slug":"evaluation-of-the-uk-vaccine-network-project-1-0-nihr207661-case-studies","status":"publish","type":"report","link":"https:\/\/technopolis-group.com\/nl\/report\/evaluation-of-the-uk-vaccine-network-project-1-0-nihr207661-case-studies\/","title":{"rendered":"Evaluation of the UK Vaccine Network Project 1.0 (NIHR207661): Case studies"},"content":{"rendered":"\n<p>Evaluation of the UK Vaccine Network Project 1.0 (NIHR207661)<\/p>\n\n\n\n<p>The study team set out to develop case studies to illustrate outcomes and impacts of the UKVN 1.0. The overarching rationale for case study selection was based on ensuring a balanced view of projects covering the diverse portfolio of investments. The selection criteria were based on:(1) funding size, delivery partner and research competitions; (2) type(s) of organisations involved; (3) type(s) of outcomes and impact as set out in the ToC; (4) Coverage of evaluation questions; (5) Availability of evidence and access to key informants; and (6) type(s) pathogens involved.<\/p>\n\n\n\n<p>A long list of case studies was developed by the study team and iterated with DHSC. This iteration allowed for an assessment of case study strengths and feasibility, in particular relation to criteria (5): availability of evidence and access to key informants. The final list of case studies is shown in Table 1 below.<\/p>\n\n\n\n<p>Read the <a href=\"https:\/\/technopolis-group.com\/wp-content\/uploads\/2025\/11\/NIHR207661_Evaluation-of-the-UKVN-Project-1.0_Final-Report.pdf\">Full report<\/a>.<\/p>\n","protected":false},"template":"","solution":[133],"sector":[69,118],"class_list":["post-62648","report","type-report","status-publish","hentry","solution-evaluation-nl","sector-health-life-sciences-nl","sector-research-innovation-nl"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.1.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Evaluation of the UK Vaccine Network Project 1.0 (NIHR207661): Case studies - Technopolis Group<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/technopolis-group.com\/nl\/report\/evaluation-of-the-uk-vaccine-network-project-1-0-nihr207661-case-studies\/\" \/>\n<meta property=\"og:locale\" content=\"nl_NL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Evaluation of the UK Vaccine Network Project 1.0 (NIHR207661): Case studies - Technopolis Group\" \/>\n<meta property=\"og:description\" content=\"Evaluation of the UK Vaccine Network Project 1.0 (NIHR207661) The [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/technopolis-group.com\/nl\/report\/evaluation-of-the-uk-vaccine-network-project-1-0-nihr207661-case-studies\/\" \/>\n<meta property=\"og:site_name\" content=\"Technopolis Group\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-25T08:25:10+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Geschatte leestijd\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minuut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/technopolis-group.com\/nl\/report\/evaluation-of-the-uk-vaccine-network-project-1-0-nihr207661-case-studies\/\",\"url\":\"https:\/\/technopolis-group.com\/nl\/report\/evaluation-of-the-uk-vaccine-network-project-1-0-nihr207661-case-studies\/\",\"name\":\"Evaluation of the UK Vaccine Network Project 1.0 (NIHR207661): Case studies - Technopolis Group\",\"isPartOf\":{\"@id\":\"https:\/\/technopolis-group.com\/nl\/#website\"},\"datePublished\":\"2025-10-07T13:01:19+00:00\",\"dateModified\":\"2025-11-25T08:25:10+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/technopolis-group.com\/nl\/report\/evaluation-of-the-uk-vaccine-network-project-1-0-nihr207661-case-studies\/#breadcrumb\"},\"inLanguage\":\"nl-NL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/technopolis-group.com\/nl\/report\/evaluation-of-the-uk-vaccine-network-project-1-0-nihr207661-case-studies\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/technopolis-group.com\/nl\/report\/evaluation-of-the-uk-vaccine-network-project-1-0-nihr207661-case-studies\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/technopolis-group.com\/nl\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Reports\",\"item\":\"https:\/\/technopolis-group.com\/de\/report\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Evaluation of the UK Vaccine Network Project 1.0 (NIHR207661): Case studies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/technopolis-group.com\/nl\/#website\",\"url\":\"https:\/\/technopolis-group.com\/nl\/\",\"name\":\"Technopolis Group\",\"description\":\"Technopolis-group\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/technopolis-group.com\/nl\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"nl-NL\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Evaluation of the UK Vaccine Network Project 1.0 (NIHR207661): Case studies - Technopolis Group","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/technopolis-group.com\/nl\/report\/evaluation-of-the-uk-vaccine-network-project-1-0-nihr207661-case-studies\/","og_locale":"nl_NL","og_type":"article","og_title":"Evaluation of the UK Vaccine Network Project 1.0 (NIHR207661): Case studies - Technopolis Group","og_description":"Evaluation of the UK Vaccine Network Project 1.0 (NIHR207661) The [&hellip;]","og_url":"https:\/\/technopolis-group.com\/nl\/report\/evaluation-of-the-uk-vaccine-network-project-1-0-nihr207661-case-studies\/","og_site_name":"Technopolis Group","article_modified_time":"2025-11-25T08:25:10+00:00","twitter_card":"summary_large_image","twitter_misc":{"Geschatte leestijd":"1 minuut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/technopolis-group.com\/nl\/report\/evaluation-of-the-uk-vaccine-network-project-1-0-nihr207661-case-studies\/","url":"https:\/\/technopolis-group.com\/nl\/report\/evaluation-of-the-uk-vaccine-network-project-1-0-nihr207661-case-studies\/","name":"Evaluation of the UK Vaccine Network Project 1.0 (NIHR207661): Case studies - Technopolis Group","isPartOf":{"@id":"https:\/\/technopolis-group.com\/nl\/#website"},"datePublished":"2025-10-07T13:01:19+00:00","dateModified":"2025-11-25T08:25:10+00:00","breadcrumb":{"@id":"https:\/\/technopolis-group.com\/nl\/report\/evaluation-of-the-uk-vaccine-network-project-1-0-nihr207661-case-studies\/#breadcrumb"},"inLanguage":"nl-NL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/technopolis-group.com\/nl\/report\/evaluation-of-the-uk-vaccine-network-project-1-0-nihr207661-case-studies\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/technopolis-group.com\/nl\/report\/evaluation-of-the-uk-vaccine-network-project-1-0-nihr207661-case-studies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/technopolis-group.com\/nl\/"},{"@type":"ListItem","position":2,"name":"Reports","item":"https:\/\/technopolis-group.com\/de\/report\/"},{"@type":"ListItem","position":3,"name":"Evaluation of the UK Vaccine Network Project 1.0 (NIHR207661): Case studies"}]},{"@type":"WebSite","@id":"https:\/\/technopolis-group.com\/nl\/#website","url":"https:\/\/technopolis-group.com\/nl\/","name":"Technopolis Group","description":"Technopolis-group","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/technopolis-group.com\/nl\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"nl-NL"}]}},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/technopolis-group.com\/nl\/wp-json\/wp\/v2\/report\/62648","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/technopolis-group.com\/nl\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/technopolis-group.com\/nl\/wp-json\/wp\/v2\/types\/report"}],"wp:attachment":[{"href":"https:\/\/technopolis-group.com\/nl\/wp-json\/wp\/v2\/media?parent=62648"}],"wp:term":[{"taxonomy":"solution","embeddable":true,"href":"https:\/\/technopolis-group.com\/nl\/wp-json\/wp\/v2\/solution?post=62648"},{"taxonomy":"sector","embeddable":true,"href":"https:\/\/technopolis-group.com\/nl\/wp-json\/wp\/v2\/sector?post=62648"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}